Alva A, Hussain M. Intermittent androgen deprivation therapy in advanced prostate cancer. Curr Treat Options Oncol 2014;15(1):127-36. Abstract

Calais da Silva FE et al. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: Results from a randomised phase 3 study of the South European Uroncological Group. Eur Urol 2009;55(6):1269-77. Abstract

Crawford ED et al. The utility of prostate-specific antigen in the management of advanced prostate cancer. BJU Int 2013;112(5):548-60. Abstract

Garcia-Albeniz X et al. Immediate versus deferred initiation of androgen deprivation therapy in prostate cancer patients with PSA-only relapse. An observational follow-up study. Eur J Cancer 2015;51(7):817-24. Abstract

Higano CS. Intermittent versus continuous androgen deprivation therapy. J Natl Compr Canc Netw 2014;12(5):727-33. Abstract

Hussain M et al. Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med 2013;368(14):1314-25. Abstract

Hussain M et al. Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: Data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916. J Clin Oncol 2009;27(15):2450-6. Abstract

Klotz L et al. Nadir testosterone within first year of androgen-deprivation therapy (ADT) predicts for time to castration-resistant progression: A secondary analysis of the PR-7 trial of intermittent versus continuous ADT. J Clin Oncol 2015;33(10):1151-6. Abstract

Klotz L et al. Intermittent androgen deprivation therapy: Clarity from confusion. Eur Urol 2013;64(5):731-3. Abstract

Loblaw DA et al. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 2007;25(12):1596-605. Abstract

Mohler JL et al. Prostate cancer, version 1.2014. J Natl Compr Canc Netw 2013;11(12):1471-9. Abstract

Mohler JL et al. Prostate cancer, Version 3.2012: Featured updates to the NCCN guidelines. J Natl Compr Canc Netw 2012;10(9):1081-7. Abstract

Morgans AK et al. Influence of age on incident diabetes and cardiovascular disease in prostate cancer survivors receiving androgen deprivation therapy. J Urol 2015;193(4):1226-31. Abstract

Salonen AJ et al. The FinnProstate Study VII: Intermittent versus continuous androgen deprivation in patients with advanced prostate cancer. J Urol 2012;187(6):2074-81. Abstract

Sciarra A et al. Intermittent androgen-deprivation therapy in prostate cancer: A critical review focused on phase 3 trials. Eur Urol 2013;64(5):722-30. Abstract